Your session is about to expire
← Back to Search
Tyrosine Kinase Inhibitor
Nivolumab + Axitinib for Advanced Melanoma
Phase 2
Waitlist Available
Led By Yana Najjar, MD
Research Sponsored by Yana Najjar
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Have unresectable (stage III) or advanced (stage IV) cutaneous or mucosal melanoma. Patients with uveal melanoma are not eligible.
Have a performance status of 0 or 1 on the ECOG Performance Scale.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is testing a new combination therapy for melanoma that has progressed despite prior treatment. The new therapy consists of two drugs given intravenously and by mouth, respectively. Patients may continue on the therapy for up to two years if it is well tolerated and effective.
Who is the study for?
This trial is for adults with stage III or IV melanoma that worsened after anti-PD1 therapy, possibly with anti-CTLA4. They must have measurable disease, be able to perform daily activities (ECOG 0 or 1), and use birth control. Excluded are those with active TB, recent major surgery or radiation, certain heart conditions, uncontrolled hypertension, known allergies to the drugs tested, some prior severe side effects from similar treatments, and pregnant or breastfeeding individuals.Check my eligibility
What is being tested?
The study tests a combination of nivolumab (an immunotherapy drug) given intravenously every four weeks and axitinib (a cancer growth blocker) taken orally twice daily. Participants can receive these medications for up to two years unless they experience significant disease progression or intolerable side effects.See study design
What are the potential side effects?
Possible side effects include high blood pressure due to axitinib; fatigue; liver issues; immune system reactions like inflammation in organs; skin reactions; digestive problems such as diarrhea; increased risk of infections due to nivolumab.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My melanoma cannot be removed by surgery and is not uveal melanoma.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Overall Response Rate (ORR)
Secondary outcome measures
Overall Survival (OS)
Progression-free Survival (PFS)
Serious Adverse Events Possibly, Probably or Definitely Related to Study Treatment
Trial Design
1Treatment groups
Experimental Treatment
Group I: Nivolumab plus AxitinibExperimental Treatment2 Interventions
Nivolumab 480mg, IV, every 4 weeks, for up to two years.
Axitinib 5mg, PO, BID, for up to two years.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Axitinib
2020
Completed Phase 2
~3050
Nivolumab
2014
Completed Phase 3
~4750
Find a Location
Who is running the clinical trial?
Yana NajjarLead Sponsor
5 Previous Clinical Trials
115 Total Patients Enrolled
5 Trials studying Melanoma
115 Patients Enrolled for Melanoma
PfizerIndustry Sponsor
4,568 Previous Clinical Trials
10,911,855 Total Patients Enrolled
51 Trials studying Melanoma
49,423 Patients Enrolled for Melanoma
Bristol-Myers SquibbIndustry Sponsor
2,638 Previous Clinical Trials
4,128,469 Total Patients Enrolled
177 Trials studying Melanoma
57,512 Patients Enrolled for Melanoma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are allergic to nivolumab or axitinib, or any of the ingredients in these medications.I am not pregnant, using birth control, sterile, or abstaining from sex for the study duration and 5 months after.I have severe heart failure.I have HIV with specific CD4 count and viral load levels.I have had a severe hypertension crisis or brain issues due to high blood pressure.I had side effects from previous cancer immunotherapy that haven't fully improved.I haven't had a heart attack, severe heart rhythm problems, stroke, or very high blood pressure needing ICU care in the last 6 months.I haven't had chemotherapy or targeted therapy in the last week and have recovered from previous treatments.My melanoma cannot be removed by surgery and is not uveal melanoma.I have never had myocarditis, Guillain-Barre syndrome, encephalitis, meningitis, transverse myelitis, Stevens-Johnson syndrome, or toxic epidermal necrolysis.I have received radiation therapy within the last 2 weeks.I do not have active brain cancer or symptoms from past brain cancer.My cancer worsened after treatment with anti-PD1, possibly with anti-CTLA4, confirmed by scans.I agree to use or continue using contraception or practice abstinence for 7 months after my last treatment dose.I have not needed systemic treatment for an autoimmune disease in the last 2 years.You have a disease that can be measured using a specific set of guidelines.I have had severe side effects from previous immune treatments that made me stop the treatment.I am not using or planning to use strong CYP3A4/5 inhibitors or eat grapefruit.I am currently on IV antibiotics for an infection.You have a history of or test positive for hepatitis B or C. If there are signs of these infections, you will be tested.I have mild to moderate nerve pain or damage but can still qualify for the study.My brain cancer has been stable for 2 weeks, either without symptoms or after treatment.I have recovered from any major surgery before starting treatment.I am not on high-dose steroids or immunosuppressants.My organs are functioning well.I have a condition that affects my ability to absorb oral medications.My blood pressure is high even with medication.I am not using or planning to use strong CYP3A4/5 inducers like carbamazepine or St. John's wort.I have an active tuberculosis infection.I have not had major surgery in the last 4 weeks.I have not received a live vaccine in the last 30 days.I am fully active or restricted in physically strenuous activity but can do light work.I have had pneumonitis treated with steroids or have it now.I have not had a major clotting or bleeding event in the last 6 months.I have another cancer, but it's either not spreading or not being treated, except for certain skin, cervical, colon cancers, or non-spreading prostate cancer.I don't need a biopsy to join, but if I can have one, I must do it now and at week 12.
Research Study Groups:
This trial has the following groups:- Group 1: Nivolumab plus Axitinib
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What have patients reported as adverse effects of Axitinib?
"Axitinib's safety is rated as a 2 by our team at Power. This reflects that, while Phase 2 trials have not yielded evidence of efficacy, there is some data supporting Axitinib's safety profile."
Answered by AI
How many individuals can enroll in this research project?
"That is correct, the clinical trial indicated on clinicaltrials.gov is still recruiting patients. This particular study was posted on December 18th, 2020 and was last edited April 19th, 2022. They are searching for 31 participants from 1 site."
Answered by AI
Are there other research papers which feature Axitinib?
"Axitinib is being trialed in 790 studies worldwide, with 86 of those in the crucial third stage. Most trials are based out of Basel, BE, but there are 40953 locations running Axitinib trials."
Answered by AI
What conditions does Axitinib commonly target?
"Axitinib is primarily used to fight malignant neoplasms, but it has also been shown to be useful in treating other conditions such as unresectable melanoma and squamous cell carcinoma."
Answered by AI
Can anyone sign up for this test currently?
"Yes, this study is looking for volunteers at the moment. According to clinicaltrials.gov, the trial was first advertised on December 18th 2020 and updated as recently as April 19th 2022."
Answered by AI
Does this trial pave the way for other similar studies?
"Axitinib has a long clinical history, with the first trial being performed in 2010. After the initial study - which only had 127 participants - Axitinib was approved for Phase 1 drugs. As of now, there are 790 live studies involving Axitinib across 2426 cities and 51 countries."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger